BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 29170919)

  • 21. HBV cure: why, how, when?
    Levrero M; Testoni B; Zoulim F
    Curr Opin Virol; 2016 Jun; 18():135-43. PubMed ID: 27447092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation.
    Burnett RJ; François G; Kew MC; Leroux-Roels G; Meheus A; Hoosen AA; Mphahlele MJ
    Liver Int; 2005 Apr; 25(2):201-13. PubMed ID: 15780040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospects for the Global Elimination of Hepatitis B.
    Block TM; Chang KM; Guo JT
    Annu Rev Virol; 2021 Sep; 8(1):437-458. PubMed ID: 34586871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune balance in Hepatitis B Infection: Present and Future Therapies.
    Vyas AK; Jindal A; Hissar S; Ramakrishna G; Trehanpati N
    Scand J Immunol; 2017 Jul; 86(1):4-14. PubMed ID: 28387980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absent inhibition of hepatitis B virus replication by azidothymidine in patients chronically coinfected by HIV-1 and HBV.
    Gallian P; De Lamballerie X; Lehucher MP; Dhiver C; Ravaux I
    New Microbiol; 1996 Apr; 19(2):167-9. PubMed ID: 8722313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Private companies: an opportunity for hepatitis B virus (HBV) prevention and care in Ivory Coast in the wake of HIV/AIDS?].
    Bekelynck A
    Bull Soc Pathol Exot; 2015 Feb; 108(1):57-62. PubMed ID: 25407333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis delta and HIV infection.
    Calle Serrano B; Manns MP; Wedemeyer H
    Semin Liver Dis; 2012 May; 32(2):120-9. PubMed ID: 22760651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis B and human immunodeficiency virus co-infection.
    Phung BC; Sogni P; Launay O
    World J Gastroenterol; 2014 Dec; 20(46):17360-7. PubMed ID: 25516647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?
    Alonso S; Guerra AR; Carreira L; Ferrer JÁ; Gutiérrez ML; Fernandez-Rodriguez CM
    BMC Gastroenterol; 2017 Dec; 17(1):168. PubMed ID: 29268704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic hepatitis B: past, present, and future.
    Lai M; Liaw YF
    Clin Liver Dis; 2010 Aug; 14(3):531-46. PubMed ID: 20638030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.
    Locarnini S; Warner N
    Antivir Ther; 2007; 12 Suppl 3():H15-23. PubMed ID: 18284179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B.
    Fung J; Lai CL; Yuen MF
    Expert Rev Anti Infect Ther; 2010 Jun; 8(6):717-26. PubMed ID: 20521898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current treatments for chronic hepatitis B virus infections.
    Zoulim F; Lebossé F; Levrero M
    Curr Opin Virol; 2016 Jun; 18():109-16. PubMed ID: 27318098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical features of acute hepatitis E super-infections on chronic hepatitis B.
    Chen C; Zhang SY; Zhang DD; Li XY; Zhang YL; Li WX; Yan JJ; Wang M; Xun JN; Lu C; Ling Y; Huang YX; Chen L
    World J Gastroenterol; 2016 Dec; 22(47):10388-10397. PubMed ID: 28058019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Latest developments in the treatment of hepatitis B.
    Dandri M; Petersen J
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of human immunodeficiency virus on viral hepatitis.
    Mallet V; Vallet-Pichard A; Pol S
    Liver Int; 2011 Jan; 31 Suppl 1():135-9. PubMed ID: 21205151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A serological and molecular survey of hepatitis B in children 15 years after inception of the national hepatitis B vaccination program in eastern China.
    Dong Y; Liu SL; Zhai XJ; Zhu FC; Pan H; Yu JX; Chen YZ; Xie YR; Zhang XY; Zhang HM; Li LJ; Wang H; Ruan B
    J Med Virol; 2009 Sep; 81(9):1517-24. PubMed ID: 19626618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease.
    Yuan Q; Song LW; Cavallone D; Moriconi F; Cherubini B; Colombatto P; Oliveri F; Coco BA; Ricco G; Bonino F; Shih JW; Xia NS; Brunetto MR
    PLoS One; 2015; 10(6):e0130209. PubMed ID: 26115521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibiting the Secretion of Hepatitis B Surface Antigen (HBsAg) to Treat Hepatitis B Infection- a Review.
    Baugh SDP
    Infect Disord Drug Targets; 2017; 17(1):24-35. PubMed ID: 28056752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. On the sexual transmission dynamics of hepatitis B virus in China.
    Zou L; Ruan S; Zhang W
    J Theor Biol; 2015 Mar; 369():1-12. PubMed ID: 25596515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.